SCHEMBL478071

SCHEMBL478071

FC1C[CH]C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL779051 0.79
SCHEMBL478035 0.79
SCHEMBL775066 0.79
SCHEMBL14890300 0.76
SCHEMBL775882 0.76
SCHEMBL82889 0.63
SCHEMBL13719072 0.63
SCHEMBL322524 0.63
SCHEMBL1173252 0.60
SCHEMBL1766118 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 734 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4399209-A1 NEW QUINOLINE DERIVATIVES Elanco Animal Health GmbH (DE) 2024-07-17 EP claimed
US-20240197888-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-06-20 US claimed
WO-2024118887-A1 N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA BLUEPRINT MEDICINES CORPORATION (US) 2024-06-06 WO claimed
US-20240174643-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2024-05-30 US claimed
WO-2024104932-A1 ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-05-23 WO claimed
CN-118019736-A Molecular gel compound designed based on cereblon protein and application thereof 标新生物医药科技(上海)有限公司 2024-05-10 CN claimed
EP-4363058-A1 AZETIDINYL PYRIMIDINES AND USES THEREOF Aerie Pharmaceuticals, Inc. (US) 2024-05-08 EP claimed
US-20240140919-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2024-05-02 US claimed
CN-117957223-A Quinoline derivatives 礼蓝动物保健有限公司 2024-04-30 CN claimed
EP-4355741-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS Biotheryx, Inc. (US) 2024-04-24 EP claimed
EP-0640142-A1 PROCESS FOR PRODUCTION OF AVERMECTINS AND CULTURES THEREFOR PFIZER INC. (US) 1995-03-01 EP claimed
EP-0276103-B1 Process for production of B avermectins and cultures therefor PFIZER (US) 1993-10-20 EP claimed
WO-1993019194-A1 PROCESS FOR PRODUCTION OF AVERMECTINS AND CULTURES THEREFOR PFIZER INC. (US) 1993-09-30 WO claimed
EP-0284176-B1 PROCESS FOR PRODUCTION OF AVERMECTINS AND CULTURES THEREFOR PFIZER INC. (US) 1993-08-25 EP claimed
EP-0313297-B1 PROCESS FOR PRODUCTION OF AVERMECTIN AGLYCONES AND CULTURES THEREFOR PFIZER INC. (US) 1993-05-19 EP claimed
EP-0276131-B1 NON-NATURAL DEMETHYLAVERMECTINS AND PROCESS THEREFOR PFIZER INC. (US) 1993-04-07 EP claimed
EP-0313297-A2 Process for production of avermectin aglycones and cultures therefor PFIZER INC. (US) 1989-04-26 EP claimed
EP-0284176-A2 Process for production of avermectins and cultures therefor PFIZER INC. (US) 1988-09-28 EP claimed
EP-0276103-A2 Process for production of B avermectins and cultures therefor PFIZER INC. (US) 1988-07-27 EP claimed
EP-0276131-A2 Non-natural demethylavermectins and process therefor PFIZER INC. (US) 1988-07-27 EP claimed